Trial success sees Clinuvel near European filing for Scenesse
20 December, 2011 by Tim DeanClinuvel’s photoprotective drug Scenesse has shown it has a significant benefit for sufferers of erythropoietic protoporphyria, bringing the company closer to filing in Europe for marketing authorisation.
A look at year that was and what’s in store for 2012
19 December, 2011 by AusBiotechIn the year that AusBiotech celebrated 25 years since it began as the Australian Biotechnology Association, 2011 has been the most action-packed for many years. Dr Anna Lavelle, CEO of AusBiotech, takes a look at the year that was and what 2012 might hold for the biotechnology sector.
HealthLinx prepares to wrap up OvPlex trial
16 December, 2011 by Dylan Bushell-EmblingDiagnostics product developer HealthLinx (ASX:HTX) will finalise recruitment for a large trial of its OvPlex ovarian cancer biomarker, on the strength of the early results.
Hunter Immunology agrees to Probiomics merger
16 December, 2011 by Dylan Bushell-EmblingThe board and largest shareholders of Hunter Immunology have agreed to endorse a reverse takeover by Probiomics (ASX:PCC) to create a company with a $37.2m market cap.
BioDiem buys Savine Therapeutics
15 December, 2011 by Dylan Bushell-EmblingVaccine company BioDiem (ASX:BDM) has added antigen development technology to its portfolio with the purchase of Savine Therapeutics.
IQnovate completes public listing on NSX
15 December, 2011 by Dylan Bushell-EmblingShares in contract medical services company IQnovate (NSX:IQN) start strong, but then pare some of their early gains, during the first day of public trading.
Compumedics wins $1m EEG deal
15 December, 2011 by Dylan Bushell-EmblingCompumedics (ASX:CMP) has picked up a deal to supply an EEG system to the Yale School of Medicine.
Government must do more to promote ethical standards in the promotion of health sector products: IVD Australia
13 December, 2011 by Tim DeanIVD Australia has expressed disappointment that the Therapeutic Goods Administration's new blueprint on regulation of the promotion of therapeutic goods doesn't do enough to raise ethical standards in the industry.
Phylogica partnership with Pfizer hits first milestone
13 December, 2011 by Tim DeanDrug discovery company Phylogica (ASX:PYC) has received its first milestone payment from a collaboration with Pfizer to discover novel peptide-based vaccines.
Government about to release $1.2 billion cleantech program for manufacturers
13 December, 2011 by AusBiotechRegistrations of interest are open now for three components of the Government's soon-to-be-released $1.2 billion Clean Technology Program.
Greg Combet takes over as Minister for Innovation
12 December, 2011 by Tim DeanA cabinet reshuffle has seen Greg Combet take over as Innovation Minister from Kim Carr, who has been demoted to the outer ministry.
DSM Biologics and AIBN partner to open biologics facility in Queensland
09 December, 2011 by Tim DeanDutch CMO DSM Biologics has signed a MoU with the Australian Institute for Bioengineering and Nanotechnology to open Australia’s largest biologics facility in Queensland.
Nanopatch wins The Australian Innovation Challenge
09 December, 2011 by Tim DeanThe needle-free vaccination technology by Vaxxas has won the overall award at the inaugural The Australian Innovation Challenge.
CSL partners with NIH for CMV trial in pregnant women
08 December, 2011 by Tim DeanCSL will contribute $2.5 million of immunoglobulin to an NIH-led trial to combat cytomegalovirus (CMV) in pregnant women to prevent congenital CMV in infants.
AVCAL calls for continued govt support for Innovation Investment Fund
08 December, 2011 by Tim DeanThe Australian Private Equity and Venture Capital Association welcomes the government's $100m funding to the Innovation Investment Fund but calls for continued policy commitment.
